Barclays »

Actuate Therapeutics shares owned by Barclays

Quarter-by-quarter ownership of Actuate Therapeutics (ACTU) shares owned by Barclays from 13F filings

Historical chart of Barclays investment in Actuate Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Actuate Therapeutics held by Barclays consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Actuate Therapeutics by Barclays

Quarter filed Position value Share count Share price at filing
2025-09-30 $59k 8.9k 6.69
2025-06-30 $227k 37k 6.08

More positions owned by Barclays

Microsoft Corporation (MSFT)
SPDR S&ampP 500 ETF TR Fund (SPY)
Invesco Qqq Tr Fund (QQQ)
NVIDIA Corporation (NVDA)
Ishares Tr Fund (IWM)
Apple (AAPL)
Tesla Opt Put Option (TSLA)
Amazon Opt Call Option (AMZN)
Alphabet Opt Call Option (GOOGL)
Broadcom Opt Call Option (AVGO)
Facebook Inc cl a (META)
Ishares Tr Opt Call Option (HYG)
JPMorgan Chase & Co. (JPM)
Alphabet Opt Put Option (GOOG)
Berkshire Hathaway Inc Del Opt Put Option (BRK.B)

View all positions for Barclays

Top funds holding Actuate Therapeutics

BIOS Capital Management
Voss Capital
Vanguard Group
BlackRock
Geode Capital Management
Northern Trust
State Street Corporation
Northwestern Mutual Wealth Management Company
Gleason Group
SFMG Wealth Advisors
LPL Financial
Charles Schwab Investment Management
Wells Fargo & Company
Royal Bank of Canada
Freestone Capital Holdings

View all funds holding Actuate Therapeutics